Clinical Trial Update: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of MLN0128 in relapsed or refractory multiple myeloma and Waldenström macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Waldenström Macroglobulinemia

Drugs mentioned

• MLN0128 (sapanisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED